Ahmet Dirican , Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on LinkedIn:
“Liquid biopsy: from potential to precision
Even at a ctDNA tumor fraction below 1%, liquid biopsy can detect key driver alterations – as shown in this case with EGFR L858R and BRCA2 Q2858* findings.
Recent advances now allow clinically actionable results even when ctDNA levels are minimal, broadening its utility beyond advanced disease to earlier stages, minimal residual disease (MRD), and treatment monitoring. Liquid biopsy is no longer a complementary test — it’s becoming a direction-defining tool in modern oncology.”
More posts featuring Liquid biopsy on OncoDaily.